<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230128057251N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-29</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Clinical evaluation the effect of Xylapi ointment and lidocaine spray on the patient's satisfaction, stress, cooperation and pain level in spinal anesthesia for cesarean section and comparing it with the control group</public_title>
      <acronym></acronym>
      <scientific_title>Clinical evaluation the effect of Xylapi ointment and lidocaine spray on the patient's satisfaction, stress, cooperation and pain level in spinal anesthesia for cesarean section and comparing it with the control group</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>258</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68263</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: We divide the patients into 3 groups by block randomization and quadruple block, totaling 86 people, which include 258 people and have a gestational age of more than 37 weeks. In the intervention group 1, which consists of 86 people, 10 grams of Xylapi ointment is used in a cross-sectional area of 10 square centimeters (according to the anesthesiologist's opinion) 20 to 30 minutes before the spinal injection in the place where the needle is inserted to create anesthesia. In the intervention group 2 as well 3 puffs of 10% lidocaine spray are used at the needle insertion site 5-10 minutes before the spinal. In the control group, 3 puffs of distilled water are used 10 minutes before the spinal, Blinding description: In this study, the subjects are aware that a new method is being studied and researched, but they are blinded to which group they belong to and which drug is being studied on them.</study_design>
      <phase>3</phase>
      <hc_freetext>caesarean  section.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group 1, which consists of 86 people, 10 grams of Xylapi ointment is used in a cross-sectional area of 10 square centimeters (according to the opinion of an anesthesiologist) 20 to 30 minutes before the spinal injection at the place where the needle is inserted to create anesthesia. Then it is patched. The preb and lid are done and the mother is put under spinal anesthesia with a G25 needle and half percent marcaine ampoule. Intervention 2: In intervention group 2, 3 puffs of 10% lidocaine spray are used at the needle insertion site 5-10 minutes before the spinal injection. Intervention 3: In the control group, 3 puffs of distilled water are used 10 minutes before spinal.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
This study aims to compare the effect of Xylapi ointment with lidocaine spray on reducing pain and anxiety during spinal surgery for cesarean section, and after collecting all the information related to the topics under study, it will be given to the researchers.

When:
After completing the data collection and writing the thesis in 1403

To whom:
Specialists in obstetrics and gynecology and anesthesia

Conditions:
Persons who have access to the information by writing a letter to the research unit of Tehran University of Medical Sciences and the holder of the code of ethics and the IRCT code by referring to the research assistant of Baharlu Hospital.

Where to obtain:
Research Unit of Tehran University of Medical Sciences, Research Vice-Chancellor of Baharlu Hospital

How to obtain:
Writing a letter with the research unit of Tehran University of Medical Sciences and receiving the code of ethics and referring to the research unit of Baharlo Hospital and receiving information

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Ghale Noie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Behdari St., Rah Ahan Sq.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1339973111</zip>
        <telephone>+98 21 5565 8500</telephone>
        <email>zgh.5068@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Ghale Noie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Behdari St., Rah Ahan Sq.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1339973111</zip>
        <telephone>+98 21 5565 8500</telephone>
        <email>zgh.5068@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women referred to Bharlo Hospital with a gestational age of more than 37 weeks who are candidates for elective cesarean section</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Gestational age below 37 weeks
Pregnant women who are candidates for emergency cesarean section
Pregnant women with chronic hypertension and diabetes
History of allergy to lidocaine
History of addiction and contraindications for spinal anesthesia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group 1, which consists of 86 people, 10 grams of Xylapi ointment is used in a cross-sectional area of 10 square centimeters (according to the opinion of an anesthesiologist) 20 to 30 minutes before the spinal injection at the place where the needle is inserted to create anesthesia. Then it is patched. The preb and lid are done and the mother is put under spinal anesthesia with a G25 needle and half percent marcaine ampoule.</i_keyword>
      <i_keyword>In intervention group 2, 3 puffs of 10% lidocaine spray are used at the needle insertion site 5-10 minutes before the spinal injection.</i_keyword>
      <i_keyword>In the control group, 3 puffs of distilled water are used 10 minutes before spinal.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount of mother's pain during spinal needle insertion. Timepoint: After caesarean section. Method of measurement: Visual Analog Scale.</prim_outcome>
      <prim_outcome>The level of mother's satisfaction during transfer to the ward (end of recovery). Timepoint: After caesarean section. Method of measurement: Visual Analog Scale.</prim_outcome>
      <prim_outcome>The level of mother's anxiety before the insertion of the spinal needle. Timepoint: After caesarean section. Method of measurement: Visual Analog Scale.</prim_outcome>
      <prim_outcome>The level of cooperation of the mother according to the anesthesiologist. Timepoint: After caesarean section. Method of measurement: Anesthesiologist grading from 1 to 10.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-23</approval_date>
        <contact_name>Research Ethics Committees Of School Of Medicine Tehran University of Medical Sciences</contact_name>
        <contact_address>Research and Technology Affairs Management Unit, Room 604, 6th Floor, Headquarters of Tehran University of Medical Sciences, Corner of Qods St, Keshavarz Blvd Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
